U.S. Physical Therapy (USPH)
(Delayed Data from NYSE)
$100.61 USD
+0.23 (0.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $100.55 -0.06 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Income Statements
Fiscal Year end for US Physical Therapy, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 605 | 553 | 495 | 423 | 482 |
Cost Of Goods | 483 | 441 | 378 | 329 | 370 |
Gross Profit | 122 | 112 | 117 | 94 | 112 |
Selling & Adminstrative & Depr. & Amort Expenses | 69 | 55 | 47 | 42 | 45 |
Income After Depreciation & Amortization | 52 | 57 | 71 | 52 | 67 |
Non-Operating Income | 7 | 5 | 3 | 15 | 6 |
Interest Expense | 9 | 6 | 1 | 2 | 2 |
Pretax Income | 49 | 56 | 73 | 66 | 71 |
Income Taxes | 12 | 12 | 15 | 13 | 14 |
Minority Interest | 9 | 11 | 17 | 17 | 17 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 37 | 43 | 58 | 52 | 57 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 28 | 32 | 41 | 35 | 40 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 86 | 81 | 82 | 63 | 78 |
Depreciation & Amortization (Cash Flow) | 34 | 24 | 12 | 11 | 10 |
Income After Depreciation & Amortization | 52 | 57 | 71 | 52 | 67 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 14.19 | 12.99 | 12.90 | 12.84 | 12.76 |
Diluted EPS Before Non-Recurring Items | 2.56 | 2.70 | 3.17 | 2.99 | 2.82 |
Diluted Net EPS (GAAP) | 1.28 | 2.25 | 2.41 | 2.48 | 2.45 |
Fiscal Year end for US Physical Therapy, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 154.80 | 150.01 | 151.49 | 148.51 |
Cost Of Goods | NA | 124.29 | 122.08 | 119.28 | 117.65 |
Gross Profit | NA | 30.52 | 27.93 | 32.21 | 30.86 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 13.90 | 12.05 | 12.15 | 13.86 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 16.62 | 15.88 | 20.06 | 17.00 |
Non-Operating Income | NA | 3.00 | 2.00 | 1.67 | -0.04 |
Interest Expense | NA | 2.01 | 2.10 | 2.63 | 2.56 |
Pretax Income | NA | 0.11 | 15.78 | 19.10 | 14.40 |
Income Taxes | NA | 1.40 | 3.56 | 4.23 | 2.97 |
Minority Interest | NA | -1.95 | 2.97 | 3.95 | 4.02 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.29 | 12.22 | 14.86 | 11.43 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 0.66 | 9.25 | 10.92 | 7.41 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 14.99 | 14.99 | 13.72 | 13.02 |
Diluted EPS Before Non-Recurring Items | NA | 0.59 | 0.62 | 0.76 | 0.59 |
Diluted Net EPS (GAAP) | NA | -0.45 | 0.51 | 0.64 | 0.58 |